Targeting cell signaling and apoptotic pathways by dietary agents: Role in the prevention and treatment of cancer

Nutrition and Cancer

Volumn 63, Issue 2, 2011, Pages 161-173

  Shanmugam, Muthu K ^a   Kannaiyan, Radhamani ^a   Sethi, Gautam ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CURCUMIN; CYCLIN D1; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIGALLOCATECHIN GALLATE; GENISTEIN; GROWTH FACTOR; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RESVERATROL; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SILYMARIN; SOMATOMEDIN RECEPTOR; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; APOPTOSIS; CANCER CELL; CANCER PREVENTION; CANCER THERAPY; COLORECTAL CANCER; DIET SUPPLEMENTATION; FRUIT; GLIOMA; HUMAN; NEOPLASM; NONHUMAN; PROSTATE CANCER; REVIEW; VEGETABLE;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CATECHIN; CLINICAL TRIALS AS TOPIC; CURCUMA; CURCUMIN; DIET; DISEASE MODELS, ANIMAL; FRUIT; GENISTEIN; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; SILYMARIN; STILBENES; UNITED STATES; VEGETABLES;

ANIMALIA; CURCUMA LONGA;

EID: 79951901778     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635581.2011.523502     Document Type: Review

References (129)

1. Aggarwal BB, Sethi G, Baladandayuthapani V, Krishnan S, and Shishodia S: Targeting cell signaling pathways for drug discovery: an old lock needs a new key. J Cell Biochem 102, 580-592, 2007. (Pubitemid 47557413)
2. Winer E, Gralow J, Diller L, Karlan B, Loehrer P, et al.: Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J Clin Oncol 27, 812-826, 2009.
3. Aggarwal BB, Danda D, Gupta S, and Gehlot P: Models for prevention and treatment of cancer: problems vs. promises. Biochem Pharmacol 78, 1083-1094, 2009.
4. Aggarwal BB, Van Kuiken ME, Iyer LH, Harikumar KB, Sung B, et al.: Molecular targets of nutraceuticals derived from dietary spices: potential role in suppression of inflammation and tumorigenesis. Exp Biol Med (Maywood) 234, 825-849, 2009.
5. Sarkar FH and Li Y: Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 66, 3347-3350, 2006.
6. Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med 10, 789-799, 2004.
7. Willett WC: Diet and health: what should we eat? Science 264, 532-537, 1994.
8. Reddy L, Odhav B, and Bhoola KD: Natural products for cancer prevention: a global perspective. Pharmacol Ther 99, 1-13, 2003. (Pubitemid 36694746)
9. Ichikawa H, Nakamura Y, Kashiwada Y, and Aggarwal BB: Anticancer drugs designed by mother nature: ancient drugs but modern targets. Curr Pharm Des 13, 3400-3416, 2007. (Pubitemid 350201674)
10. Mathew A, Peters U, Chatterjee N, Kulldorff M, Sinha R, et al.: Fat, fiber, fruits, vegetables, and risk of colorectal adenomas. Int J Cancer 108, 287-292, 2004. (Pubitemid 37541785)
11. Khan N, Afaq F, and Mukhtar H: Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal 10, 475-510, 2008.
12. Sethi G, Sung B, and Aggarwal BB: TNF: amaster switch for inflammation to cancer. Front Biosci 13, 5094-5107, 2008.
13. Baud V and Karin M: Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8, 33-40, 2009.
14. Sethi G, Sung B, and Aggarwal BB: Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood) 233, 21-31, 2008.
15. Sethi G and Tergaonkar V: Potential pharmacological control of the NF-kappaB pathway. Trends Pharmacol Sci 30, 313-321, 2009.
16. Aggarwal BB, Ichikawa H, Garodia P, Weerasinghe P, Sethi G, et al.: From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer. Expert Opin Ther Targets 10, 87-118, 2006. (Pubitemid 43263269)
17. Kaefer CM and Milner JA: The role of herbs and spices in cancer prevention. J Nutr Biochem 19, 347-361, 2008. (Pubitemid 351689086)
18. Aggarwal BB and Shishodia S: Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann NY Acad Sci 1030, 434-441, 2004. (Pubitemid 40378943)
19. Kawamori T, Lubet R, Steele VE, Kelloff GJ, Kaskey RB, et al.: Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 59, 597-601, 1999. (Pubitemid 29076056)
20. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, et al.: Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 11, 7490-7498, 2005. (Pubitemid 41507710)
21. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, et al.: Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 13, 3423-3430, 2007. (Pubitemid 46944931)
22. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, et al.: Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67, 3853-3861, 2007. (Pubitemid 46762173)
23. Kunnumakkara AB, Diagaradjane P, Guha S, Deorukhkar A, Shentu S, et al.: Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res 14, 2128-2136, 2008. (Pubitemid 351551125)
24. Kamat AM, Tharakan ST, Sung B, and Aggarwal BB: Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res 69, 8958-8966, 2009.
25. Moghaddam SJ, Barta P, Mirabolfathinejad SG, Ammar-Aouchiche Z, Garza NT, et al.: Curcumin inhibits COPD-like airway inflammation and lung cancer progression in mice. Carcinogenesis 30, 1949-1956, 2009.
26. Kunnumakkara AB, Diagaradjane P, Anand P, Harikumar KB, Deorukhkar A, et al.: Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF, and CXCR4 expression in an orthotopic mouse model. Int J Cancer 125, 2187-2197, 2009.
27. Sung B, Kunnumakkara AB, Sethi G, Anand P, Guha S, et al.: Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 8, 959-970, 2009.
28. Tharakan ST, Inamoto T, Sung B, Aggarwal BB, and Kamat AM: Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers. Biochem Pharmacol 79, 218-228, 2010.
29. Banerjee S, Bueso-Ramos C, and Aggarwal BB: Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 62, 4945-4954, 2002. (Pubitemid 34984418)
30. Afaq F, Ahmad N, and Mukhtar H: Suppression of UVB-induced phosphorylation ofmitogen-activated protein kinases and nuclear factor kappaBby green tea polyphenol in SKH-1 hairless mice. Oncogene 22, 9254-9264, 2003.
31. Siddiqui IA, Shukla Y, Adhami VM, Sarfaraz S, Asim M, et al.: Suppression of NFkappaB and its regulated gene products by oral administration of green tea polyphenols in an autochthonous mouse prostate cancer model. Pharm Res 25, 2135-2142, 2008.
32. Aggarwal BB and Sung B: Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 30, 85-94, 2009.
33. Matthews CP, Colburn NH, and Young MR: AP-1 a target for cancer prevention. Curr Cancer Drug Targets 7, 317-324, 2007. (Pubitemid 46849236)
34. Eferl R and Wagner EF: AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3, 859-868, 2003. (Pubitemid 37383716)
35. Shaulian E and Karin M: AP-1 as a regulator of cell life and death. Nat Cell Biol 4, E131-136, 2002.
36. Chainy GB, Manna SK, Chaturvedi MM, and Aggarwal BB: Anethole blocks both early and late cellular responses transduced by tumor necrosis factor: effect on NF-kappaB, AP-1, JNK, MAPKK, and apoptosis. Oncogene 19, 2943-2950, 2000. (Pubitemid 30389084)
37. Bierhaus A, Zhang Y, Quehenberger P, Luther T, Haase M, et al.: The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-kappa B. Thromb Haemost 77, 772-782, 1997. (Pubitemid 27182979)
38. Nakamura K, Yasunaga Y, Segawa T, Ko D, Moul JW, et al.: Curcumin downregulates AR gene expression and activation in prostate cancer cell lines. Int J Oncol 21, 825-830, 2002.
39. Ichiki K, Mitani N, Doki Y, Hara H, Misaki T, et al.: Regulation of activator protein-1 activity in the mediastinal lymph node metastasis of lung cancer. Clin Exp Metastasis 18, 539-545, 2000. (Pubitemid 32964315)
40. Dickinson SE, Melton TF, Olson ER, Zhang J, Saboda K, et al.: Inhibition of activator protein-1 by sulforaphane involves interaction with cysteine in the cFos DNA-binding domain: implications for chemoprevention of UVB-induced skin cancer. Cancer Res 69, 7103-7110, 2009.
41. Manna SK, Mukhopadhyay A, and Aggarwal BB: Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 164, 6509-6519, 2000. (Pubitemid 30408836)
42. Kundu JK, Chun KS, Kim SO, and Surh YJ: Resveratrol inhibits phorbol ester-induced cyclooxygenase-2 expression in mouse skin: MAPKs and AP-1 as potential molecular targets. Biofactors 21, 33-39, 2004. (Pubitemid 40921823)
43. Yeh MH, Kao ST, Hung CM, Liu CJ, Lee KH, et al.: Hesperidin inhibited acetaldehyde-induced matrix metalloproteinase-9 gene expression in human hepatocellular carcinoma cells. Toxicol Lett 184, 204-210, 2009.
44. Staniforth V, Chiu LT, and Yang NS: Caffeic acid suppresses UVB radiation-induced expression of interleukin-10 and activation of mitogen-activated protein kinases in mouse. Carcinogenesis 27, 1803-1811, 2006.
45. Liu P, Cheng H, Roberts TM, and Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8, 627-644, 2009.
46. Engelman JA: Targeting PI3K signalling in cancer: opportunities, challenges, and limitations. Nat Rev Cancer 9, 550-562, 2009.
47. Kumar AP, Garcia GE, Ghosh R, Rajnarayanan RV, Alworth WL, et al.: 4-Hydroxy-3-methoxybenzoic acid methyl ester: a curcumin derivative targets Akt/NF kappa B cell survival signaling pathway: potential for prostate cancer management. Neoplasia 5, 255-266, 2003. (Pubitemid 36754055)
48. Li M, Zhang Z,Hill DL, Wang H, Zhang R, et al.:Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by downregulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 67, 1988-1996, 2007.
49. Li Y and Sarkar FH: Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 8, 2369-2377, 2002. (Pubitemid 34753612)
50. Tang FY, Nguyen N, and Meydani M: Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VE-cadherin phosphorylation and inactivation of Akt molecule. Int J Cancer 106, 871-878, 2003. (Pubitemid 37071665)
51. Siddiqui IA, Adhami VM, Afag F, Ahmad N, Mukhtar, et al.: Modulation of phosphatidylinositol-3-kinase/protein kinase B- and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells. J Cell Biochem 91, 232-242, 2004.
52. Adhami VM, Siddiqui IA, Ahmad N, Gupta S, and Mukhtar H: Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 64, 8715-8722, 2004. (Pubitemid 39552088)
53. Yi T, Cho SG, Yi Z, Pang X, Rodriguez M, et al.: Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther 7, 1789-1796, 2008.
54. Wagner EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9, 537-549, 2009.
55. Sebolt-Leopold JS: Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19, 6594-6599, 2000.
56. Chen YR and Tan TH: Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 17, 173-178, 1998.
57. Li Y, Li X, and Sarkar FH: Gene expression profiles of I3C- and DIM-treated PC3 human prostate cancer cells determined by cDNA microarray analysis. J Nutr 133, 1011-1019, 2003. (Pubitemid 36407118)
58. Filomeni G, Graziani I, Rotilio G, and Ciriolo MR: trans-Resveratrol induces apoptosis in human breast cancer cells MCF-7 by the activation of MAP kinases pathways. Genes Nutr 2, 295-305, 2007.
59. Vayalil PK and Katiyar SK: Treatment of epigallocatechin-3-gallate inhibits matrix metalloproteinases-2 and -9 via inhibition of activation of mitogen-activated protein kinases, c-jun and NF-kappaB in human prostate carcinoma DU-145 cells. Prostate 59, 33-42, 2004. (Pubitemid 38387841)
60. Harper CE, Patel BB, Wang J, Eltoum IA, and Lamartiniere CA: Epigallocatechin-3-gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action. Prostate 67, 1576-1589, 2007. (Pubitemid 47536156)
61. Yu H, PardollD, and Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9, 798-809, 2009.
62. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, et al.: Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann NY Acad Sci 1171, 59-76, 2009.
63. Aggarwal BB, Sethi Gr, Ahn KS, Sandur SK, Pandey MK, et al.: Targeting signal-transducer and activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann NY Acad Sci 1091, 151-169, 2006. (Pubitemid 47092233)
64. Bharti AC, Donato N, and Aggarwal BB: Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171, 3863-3871, 2003. (Pubitemid 37254592)
65. Kotha A, Sekharam M, Cilenti L, Siddiqui K, Khaled A, et al.: Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther 5, 621-629, 2006.
66. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, et al.: Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through downregulation of STAT3 and nuclear factor-kappaB- regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 109, 2293-2302, 2007. (Pubitemid 46425866)
67. Pandey MK, Sung B, Ahn KS, and Aggarwal BB: Butein suppresses constitutive and inducible signal transducer and activator of transcription (STAT) 3 activation and STAT3-regulated gene products through the induction of a protein tyrosine phosphatase SHP-1. MolPharmacol 75, 525-533, 2009.
68. Bhutani M, Pathak AK, Nair AS, Kunnumakkara AB, Guha S, et al.: Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation. Clin Cancer Res 13, 3024-3032, 2007. (Pubitemid 46849579)
69. Hahn WC and Weinberg RA: Rules formaking human tumor cells. N Engl J Med 347, 1593-1603, 2002.
70. Liang YC, Lin-shiau SY, Chen CF, and Lin JK: Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. J Cell Biochem 67, 55-65, 1997.
71. Shimizu M, Deguchi A, Lim JT, Moriwaki H, Kopelovich L, et al.: (-)- Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res 11, 2735-2746, 2005. (Pubitemid 40569476)
72. Adhami VM, Siddiqui IA, Sarfaraz S, Khwaja SI, Hafeez BB, et al.: Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clin Cancer Res 15, 1947-1953, 2009.
73. Provinciali M, Re F, Donnini A, Orlando F, Bartozzi B, et al.: Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer 115, 36-45, 2005. (Pubitemid 40559666)
74. Wu X, Lee VC, Chevalier E, and Hwang ST: Chemokine receptors as targets for cancer therapy. Curr Pharm Des 15, 742-757, 2009.
75. Vandercappellen J, Van Damme J, and Struyf S: The role of CXC chemokines and their receptors in cancer. Cancer Lett 267, 226-244, 2008.
76. Herman JG, Stadelman HL, and Roselli CE: Curcumin blocks CCL2-induced adhesion, motility and invasion, in part, through down-regulation of CCL2 expression and proteolytic activity. Int J Oncol 34, 1319-1327, 2009.
77. Skommer J, Wlodkowic D, and Pelkonen J: Gene-expression profiling during curcumin-induced apoptosis reveals downregulation of CXCR4. Exp Hematol 35, 84-95, 2007. (Pubitemid 46014374)
78. Sung B, Jhurani S, Ahn KS, Mastuo Y, Yi T, et al.: Zerumbone downregulates chemokine receptor CXCR4 expression leading to inhibition of CXCL12-induced invasion of breast and pancreatic tumor cells. Cancer Res 68, 8938-8944, 2008.
79. Harris RE: Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17, 55-67, 2009.
80. Dannenberg AJ and Subbaramaiah K: Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4, 431-436, 2003. (Pubitemid 38050040)
81. Li ZG, Hong T, Shimada Y, Komoto I, Kawabe A, et al.: Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis 23, 1531-1536, 2002.
82. Smith WL, DeWitt DL, and Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69, 145-182, 2000.
83. Kim JK and Diehl JA: Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 220, 292-296, 2009.
84. MukhopadhyayA,Banerjee S, Stafford LJ, Xia C, Liu M, et al.: Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 21, 8852-8861, 2002.
85. Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero PM, and Castellon EA: Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl 28, 282-293, 2007. (Pubitemid 46423911)
86. Gupta S, Hussain T, and Mukhtar H: Molecular pathway for (-)- epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys 410, 177-185, 2003. (Pubitemid 36268810)
87. Agarwal C, Sharma Y, and Agarwal R: Anticarcinogenic effect of a polyphenolic fraction isolated from grape seeds in human prostate carcinoma DU145 cells: modulation of mitogenic signaling and cell-cycle regulators and induction of G1 arrest and apoptosis. Mol Carcinog 28, 129-138, 2000. (Pubitemid 30612992)
88. Dass CR and Choong PF: Cancer angiogenesis: targeting the heel of Achilles. J Drug Target 16, 449-454, 2008. (Pubitemid 352015813)
89. Kim JH, Shim JS, Lee SK, Kim KW, Rha SY, et al.: Microarray-based analysis of anti-angiogenic activity of demethoxycurcumin on human umbilical vein endothelial cells: crucial involvement of the down-regulation of matrix metalloproteinase. Jpn J Cancer Res 93, 1378-1385, 2002. (Pubitemid 36104878)
90. Tseng SH, Lin SM, Chen JC, Su YH, Huang HY, et al.: Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin Cancer Res 10, 2190-2202, 2004.
91. Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, et al.: VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 104, 788-794, 2004. (Pubitemid 38970575)
92. Neuhaus T, Pabst S, Stier S, Weber AA, Schror K, et al.: Inhibition of the vascular-endothelial growth factor-induced intracellular signaling and mitogenesis of human endothelial cells by epigallocatechin-3 gallate. Eur J Pharmacol 483, 223-227, 2004. (Pubitemid 38068403)
93. Pang X, Yi Z, Zhang X, Sung B, Qu W, et al.: Acetyl-11-keto-beta- boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res 69, 5893-5900, 2009.
94. Lee MJ, Kim YS, Kummar S, Giaccone G, Trepel JB, et al.: Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol 20, 639-649, 2008.
95. Dashwood RH, Myzak MC, and Ho E: Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? Carcinogenesis 27, 344-349, 2006.
96. Liu HL, Chen Y, Cui GH, and Zhou JF: Curcumin, a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation. Acta Pharmacol Sin 26, 603-609, 2005. (Pubitemid 40676173)
97. Myzak MC, Karplus PA, Chung FL, and Dashwood RH: A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res 64, 5767-5774, 2004. (Pubitemid 39095576)
98. Myzak MC, Hardin K, Wang R, Dashwood RH, and Ho E: Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. Carcinogenesis 27, 811-819, 2006.
99. Pledgie-Tracy A, Sobolewski MD, and Davidson NE: Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol Cancer Ther 6, 1013-1021, 2007. (Pubitemid 46554571)
100. Myzak MC, Tong P, Dashwood WM, Dashwood RH, and Ho E: Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med (Maywood) 232, 227-234, 2007. (Pubitemid 46203291)
101. Myzak MC, Tong P, Dashwood WM, Orner GA, Ho E, and Dashwood RH: Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J 20, 506-508, 2006. (Pubitemid 46671231)
102. Tsukamoto S and Yokosawa H: Targeting the proteasome pathway. Expert Opin Ther Targets 13, 605-621, 2009.
103. Yang H, Landis-Piwowar KR, Chen D, Milacic V, and Dou QP: Natural compounds with proteasome inhibitory activity for cancer prevention and treatment. Curr Protein Pept Sci 9, 227-239, 2008. (Pubitemid 351997839)
104. Lam WH, Kazi A, Kuhn DJ, Chow LM, Chan AS, et al.: A potential prodrug for a green tea polyphenol proteasome inhibitor: evaluation of the peracetate ester of (-)-epigallocatechin gallate [(-)-EGCG]. Bioorg Med Chem 12, 5587-5593, 2004. (Pubitemid 39304058)
105. Nam S, Smith DM, and Dou QP: Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 276, 13322-13330, 2001.
106. Landis-Piwowar KR, Huo C, Chen D, Milacic V, Shi G, et al.: A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res 67, 4303-4310, 2007. (Pubitemid 46815078)
107. Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar AP, et al.: Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res 68, 7283-7292, 2008.
108. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3, 768-780, 2003.
109. Bharti AC and Aggarwal BB: Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 64, 883-888, 2002. (Pubitemid 35238030)
110. Anto RJ, Mukhopadhyay A, Denning K, and Aggarwal BB: Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis 23, 143-150, 2002.
111. Shishodia S, Amin HM, Lai R, and Aggarwal BB: Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 70, 700-713, 2005. (Pubitemid 41058705)
112. Bharti AC, Donato N, Singh S, and Aggarwal BB: Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101, 1053-1062, 2003. (Pubitemid 36139379)
113. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, et al.: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24, 2783-2840, 2004. (Pubitemid 39409568)
114. Samudio I, KohopleraM, Safe S, McQueen T, AndreeffM, et al.: Guggul-sterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione structure. Mol Cancer Ther 4, 1982-1992, 2005.
115. Hastak K, Gupta S, Ahmad N, Agarwal MK, Agarwal ML, et al.: Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 22, 4851-4859, 2003. (Pubitemid 36981273)
116. Kuo PL and Lin CC: Green tea constituent (-)-epigallocatechin-3-gallate inhibits Hep G2 cell proliferation and induces apoptosis through p53-dependent and Fas-mediated pathways. J Biomed Sci 10, 219-227, 2003.
117. Bode AM, Ma WY, Surh YJ, and Dong Z: Inhibition of epidermal growth factor-induced cell transformation and activator protein 1 activation by [6]-gingerol. Cancer Res 61, 850-853, 2001.
118. Keum YS, Kim J, Lee KH, Park KK, Surh YJ, et al.: Induction of apoptosis and caspase-3 activation by chemopreventive [6]-paradol and structurally related compounds in KB cells. Cancer Lett 177, 41-47, 2002. (Pubitemid 34075291)
119. Miyoshi N, Nakamura Y, Ueda Y, AbeM, Ozawa Y, et al.: Dietary ginger constituents, galanals A and B, are potent apoptosis inducers in Human T lymphoma Jurkat cells. Cancer Lett 199, 113-119, 2003. (Pubitemid 37297704)
120. El-Najjar N, Chatila M, Moukadem H, Vuorela H, Ocker M, et al.: Reactive oxygen species mediate thymoquinone-induced apoptosis and activate ERK and JNK signaling. Apoptosis 15, 183-195, 2010.
121. Samaha HS, Kelloff GJ, Steele V, Rao CV, and Reddy BS: Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res 57, 1301-1305, 1997. (Pubitemid 27152555)
122. Khor TO, Keum YS, Lin W, Kim JH, Hu R, et al.: Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res 66, 613-621, 2006. (Pubitemid 43165919)
123. Shankar S, Ganapathy S, Chen Q, and Srivastava RK: Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol Cancer 7, 16, 2008.
124. Aziz MH, Reagan-Shaw S, Wu J, and Longley BJ: Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease? FASEB J 19, 1193-1195, 2005.
125. Wang TT, Hudson TS, Wang TC, Remsberg CM, et al.: Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis 29, 2001-2010, 2008.
126. Seeni A, Takahashi S, Takeshita K, Tang M, Sugiura S, et al.: Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac J Cancer Prev 9, 7-14, 2008.
127. Lu YP, Lou YR, Xie JG, Peng QY, Liao J, et al.: Topical applications of caffeine or (-)-epigallocatechin gallate (EGCG) inhibit carcinogenesis and selectively increase apoptosis in UVB-induced skin tumors in mice. Proc Natl Acad Sci USA 99, 12455-12460, 2002.
128. Kumara SS and Huat BT: Extraction, isolation, and characterization of antitumor principle, alpha-hederin, from the seeds ofNigella sativa. Planta Med 67, 29-32, 2001. (Pubitemid 32199941)
129. Baliga MS, Meleth S, and Katiyar SK: Growth inhibitory and antimetastatic effect of green tea polyphenols on metastasis-specific mouse mammary carcinoma 4T1 cells in vitro and in vivo systems. Clin Cancer Res 11, 1918-1927, 2005.